CoChat

Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response

Open access
Szokalska, Angelika, Makowski, Marcin, Nowis, Dominika, Wilczyński, Grzegorz M., Kujawa, Marek, Wójcik, Cezary, Młynarczuk-Biały, Izabela, Salwa, Pawel, Bil, Jacek, Janowska, Sylwia, Agostinis, Patrizia, Verfaillie, Tom, Bugajski, Marek, Gietka, Jan, Issat, Tadeusz, Głodkowska, Eliza, Mrówka, Piotr, Stoklosa, Tomasz, Hamblin, Michael R., Mróz, Paweł, Jakóbisiak, Marek, Golab, Jakub · 2009 · Cancer Research
Cited by 102

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Photodynamic therapy (PDT) is an approved therapeutic procedure that exerts cytotoxic activity toward tumor cells by inducing production of reactive oxygen species such as singlet oxygen. PDT leads to oxidative damage of cellular macromolecules, including proteins that undergo multiple modifications such as fragmentation, cross-linking, and carbonylation that result in protein unfolding and aggregation. Because the major mechanism for elimination of carbonylated proteins is their degradation by proteasomes, we hypothesized that a combination of PDT with proteasome inhibitors might lead to accumulation of carbonylated proteins in endoplasmic reticulum (ER), aggravated ER stress, and potentiated cytotoxicity toward tumor cells. We observed that Photofrin-mediated PDT leads to robust carbonylation of cellular proteins and induction of unfolded protein response. Pretreatment of tumor cells with three different proteasome inhibitors, including bortezomib, MG132, and PSI, gave increased accumulation of carbonylated and ubiquitinated proteins in PDT-treated cells. Proteasome inhibitors effectively sensitized tumor cells of murine (EMT6 and C-26) as well as human (HeLa) origin to PDT-mediated cytotoxicity. Significant retardation of tumor growth with 60% to 100% complete responses was observed in vivo in two different murine tumor models (EMT6 and C-26) when PDT was combined with either bortezomib or PSI. Altogether, these observations indicate that combination of PDT with proteasome inhibitors leads to potentiated antitumor effects. The results of these studies are of immediate clinical application because bortezomib is a clinically approved drug that undergoes extensive clinical evaluations for the treatment of solid tumors. [Cancer Res 2009;69(10):4235–43]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-3439

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 102

Metadata

Authors
Szokalska, A., Makowski, M., Nowis, D., Wilczyński, G. M., Kujawa, M., Wójcik, C., Młynarczuk-Biały, I., Salwa, P., Bil, J., Janowska, S., Agostinis, P., Verfaillie, T., Bugajski, M., Gietka, J., Issat, T., Głodkowska, E., Mrówka, P., Stoklosa, T., Hamblin, M. R., Mróz, P., Jakóbisiak, M., & Golab, J.
Venue
Cancer Research
Published
2009-05-15
Volume
69
Issue
10
Pages
4235-4243
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2045843284
Cited by
102
References
4
FWCI
6.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-3439
The paper
Szokalska, A., Makowski, M., Nowis, D., Wilczyński, G. M., Kujawa, M., Wójcik, C., Młynarczuk-Biały, I., Salwa, P., Bil, J., Janowska, S., Agostinis, P., Verfaillie, T., Bugajski, M., Gietka, J., Issat, T., Głodkowska, E., Mrówka, P., Stoklosa, T., Hamblin, M. R., . . . Golab, J. (2009). Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-3439

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.